Response Evaluation Criteria

Baseline findings establish the reference point against which later examinations are compared. Follow-up imaging or other documented assessments then show whether measurable tumor burden has changed from that starting condition. Using the same reference framework helps distinguish genuine change from an isolated observation and makes treatment responses more comparable across different assessment points.

Thresholds provide consistent boundaries for interpreting changes in measurable tumor burden, while scheduled assessment intervals identify when those changes should be evaluated. Together, they reduce subjective interpretation and help separate treatment benefit from progressive disease. This consistency supports more reliable clinical decisions and allows results from separate studies to be compared using a common approach.

These outcome categories describe different patterns observed when baseline and follow-up findings are compared. Complete response and partial response indicate degrees of treatment-related improvement, stable disease indicates no qualifying change toward either response or progression, and progressive disease indicates worsening findings. The assigned category depends on the framework’s defined thresholds and assessment timing.

Clinicians first document relevant baseline findings, then obtain follow-up assessments at defined intervals. They compare the new findings with the baseline, apply the framework’s thresholds, and assign an outcome category such as complete response, partial response, stable disease, or progressive disease. The resulting classification can support decisions about continuing or adjusting therapy.

A standardized response category gives clinicians a structured way to judge whether therapy appears beneficial, whether disease remains stable, or whether findings indicate progression. That information can inform treatment adjustments and ongoing monitoring. Because the assessment uses defined comparisons rather than an isolated impression, it strengthens communication about the patient’s course and response.

Clinical trials need reproducible endpoints so investigators can evaluate therapies consistently across participants and studies. Applying the same baseline comparisons, follow-up intervals, thresholds, and response categories creates a shared basis for reporting treatment effects. These standardized outcomes improve research comparisons and help connect trial findings with the monitoring of patient outcomes in clinical practice.